1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent Glioma: new trials by email Literature Review of Recurrent Glioma trials Research Report on Recurrent Glioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) Vorasidenib, Matching Placebo - Grade 2 Glioma, Residual Glioma | Phase 3 | Active not recruiting | Institut de Recherches Internationales Servier | 331 | 2020-01-05 | 2025-04-03 |
Glioma (1)
Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Nerve Tissue (1) · Neoplasms, Neuroepithelial (1) · Neuroectodermal Tumors (1)
vorasidenib (1)
Institut de Recherches Internationales Servier (1)
Canada (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Spain (1) · Switzerland (1) · United Kingdom (1) · United States (1)
2019 (1)